Literature DB >> 30954429

Modulation of mitochondrial dysfunction for treatment of disease.

Michael Webb1, Dionisia P Sideris2, Margaret Biddle3.   

Abstract

Mitochondrial dysfunction is a causative and/or exacerbating feature of many pathologies. We discuss below approaches to modulate mitochondrial dysfunction that involve (1) increasing their energetic efficiency by targeting gene expression regulators such as PPAR or AMPK, (2) using antioxidant compounds to reduce the toxic reactive oxygen species mitochondria produce under stress, or (3) modulating aspects on the innate mitochondrial quality control system. The latter comprise linked processes of biogenesis, dynamic morphological changes, and elimination of defective mitochondria by mitophagy. We discuss representative compounds in all three classes.
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Biogenesis; Dynamics; Energetics; Mitochondria; ROS

Year:  2019        PMID: 30954429     DOI: 10.1016/j.bmcl.2019.03.041

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  5 in total

1.  Mitochondrial dysfunction and Alzheimer's disease: prospects for therapeutic intervention.

Authors:  Ji Woong Lim; Jiyoun Lee; Ae Nim Pae
Journal:  BMB Rep       Date:  2020-01       Impact factor: 4.778

2.  Tang Luo Ning, a Traditional Chinese Compound Prescription, Ameliorates Schwannopathy of Diabetic Peripheral Neuropathy Rats by Regulating Mitochondrial Dynamics In Vivo and In Vitro.

Authors:  Jiayue Zhu; Xinwei Yang; Xiao Li; Shuo Han; Yanbo Zhu; Liping Xu
Journal:  Front Pharmacol       Date:  2021-05-14       Impact factor: 5.810

3.  Genomic and Phenotypic Characterization of Experimentally Selected Resistant Leishmania donovani Reveals a Role for Dynamin-1-Like Protein in the Mechanism of Resistance to a Novel Antileishmanial Compound.

Authors:  Aya Hefnawy; Gabriel Negreira; Marlene Jara; James A Cotton; Ilse Maes; Erika D'Haenens; Hideo Imamura; Bart Cuypers; Pieter Monsieurs; Christina Mouchtoglou; Hans De Winter; Isabel Pintelon; Jean-Pierre Timmermans; Matt Berriman; Mandy Sanders; Julio Martin; Geraldine de Muylder; Jean-Claude Dujardin; Yann G-J Sterckx; Malgorzata Anna Domagalska
Journal:  mBio       Date:  2022-01-11       Impact factor: 7.867

Review 4.  The Challenge of Disease-Modifying Therapies in Parkinson's Disease: Role of CSF Biomarkers.

Authors:  Federico Paolini Paoletti; Lorenzo Gaetani; Lucilla Parnetti
Journal:  Biomolecules       Date:  2020-02-19

5.  Skeletal muscle energetics in patients with moderate to advanced kidney disease.

Authors:  Lale Ertuglu; Abdulmecit Yildiz; Jorge Gamboa; T Alp Ikizler
Journal:  Kidney Res Clin Pract       Date:  2022-01-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.